Rechercher des projets européens

11 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 
... moderate-dose DFP (30 mg/kg/day) slows the progression of handicap in de novo PD patients while not affecting systemic parameters. The 9-month, parallel-group, randomized, placebo-controlled, multicentre trial will be followed by a 1-month wash-out period. The primary efficacy criterion will be the change in motor and non-motor handicap scores on the Total Movement Disorders Society Unified Parki ...
Voir le projet

 17

 TERMINÉ 

DC-based immunotherapy to treat Malignant Mesothelioma (H2020MM04)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millio ...
Voir le projet

 8

 TERMINÉ 

DIabetes REsearCh on patient sTratification (DIRECT)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2019,

The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies.There is heterogeneity in who develops diabetes, the rate at which th ...
Voir le projet

 27

 TERMINÉ 
... cable dose adjustments during treatment and thus (iii) to improve efficacy while reducing risk of EDR or adverse effects.The MON4STRAT approach will be validated through a prospective, multicentre, randomized clinical trial with150 adults. Its applicability in paediatrics will be tested through an observational study with 70 children/neonates.Being generic in nature, MON4STRAT will be replicable t ...
Voir le projet

 13

 TERMINÉ 
The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 
Alzheimer’s disease (AD) is an ever-increasing public health concern among the aging population and is the most common form of dementia affecting more than 15 million individuals worldwide and around 5 million Europeans. The direct and indirect costs of AD and other dementias amount to more than €440,000 million each year (www.alz.org, 2010).Even modest therapeutic advances that delay disease onse ...
Voir le projet

 17

 TERMINÉ 
The therapeutic effect of the photodynamic therapy (PDT) depends on a combination of parameters that include drug dose, drug-light interval, oxygen in cells and light irradiance rate. It also varies according to the wavelength distribution of the light source. Finally, a homogeneous and reproducible illumination during the clinical PDT is determinant in preventing under- or overtreatment. So, the ...
Voir le projet

 12

 TERMINÉ 
"Type 1 diabetes is caused by an inflammatory process which damage insulin-producing beta-cells in the pancreas. It is one of the most common chronic diseases and its incidence is rapidly increasing. Due to its complications it causes a significant medical and economic burden to European society. A causal association between enterovirus and type 1 diabetes has become more and more likely. The aim ...
Voir le projet

 14

 TERMINÉ 
"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Voir le projet

 12

 TERMINÉ 
Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Voir le projet

 19

 TERMINÉ 

PATIENT SAFETY THROUGH INTELLIGENT PROCEDURES IN MEDICATION (PSIP)

Date du début: 1 janv. 2008, Date de fin: 31 juil. 2011,

Adverse Drug Events (ADE) due to product safety problems, and medication errors due to human factors (HF) are a major Public Health issue. They endanger the patients' safety and originate considerable extra hospital costs.Healthcare ICT applications should help reducing the prevalence of preventable ADE, by providing healthcare professionals and patients with relevant knowledge (guidelines, recomm ...
Voir le projet

 13